Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of upadacitinib in adult axial spondyloarthritis
jRCT2080224977Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA) (4 arms), sponsored by AbbVie Inc. Started Dec 2019; status: completed.
02
Drugs
upadacitinib
03
Conditions
ankylosing spondylitis (AS)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on jRCT2080224977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224977.